Premium
Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report
Author(s) -
Miklos Udvardy,
Strugov Vladimir,
Lewerin Catharina,
Grosicki Sebastian,
Mazur Grzegorz,
Steurer Michael,
Montillo Marco,
Kryachok Irina,
Middeke Jan M.,
Rekhtman Grygoriy,
Stefanelli Tommaso,
Vincent Ghislaine,
Govindaraju Sameera,
Österborg Anders
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16429
Subject(s) - ofatumumab , medicine , fludarabine , chronic lymphocytic leukemia , interim analysis , refractory (planetary science) , oncology , placebo , clinical trial , surgery , chemotherapy , leukemia , pathology , cyclophosphamide , physics , astrobiology , alternative medicine
Summary In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine‐refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician’s choice. The five‐year follow‐up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small‐molecule inhibitors. Ofatumumab is a well‐tolerable treatment option in multiresistant advanced CLL.